|
- 2019
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancerDOI: 10.1038/s41523-018-0097-z Abstract: Progression-free survival. a Investigator-assessed and b Independent central review in the intent-to-treat population. NR, not reache
|